What should long-term AVR evidence change in clinical practice? This webinar is in just a few days on Monday 17 August – 'Nail It With Nadira: The Next Chapter in AV Replacement' – bringing together international experts to discuss durability, valve selection and reintervention planning. Reserve your seat 👉 ow.ly/iAUQ50Zy6X5 Hear practical perspectives from Dr Nadira Hamid, Dr John Forrest, Dr Giuseppe Tarantini, Dr Tsuyoshi Kaneko and Prof Nicolas Van Mieghem on translating evolving evidence into lifetime patient management. ⏰ 12:00 CDT | 13:00 EDT | 18:00 BST This webinar is supported by an unrestricted educational grant from Edwards Lifesciences. #StructuralHeart #TAVR #AorticValve #HeartTeam #InterventionalCardiology

Congrats to Dr. Hamid for your leadership role as Global Co PI for the TRIVITA US IDE pivotal study for a new transcatheter tricuspid valve replacement system! We are proud to witness research collaboration that brings together cross-functional expertise for patients!

The procedure was performed by Dr. @kvoudris, Dr @bapat_savrtavr , Dr @HamidNadira, Dr @MHIValveDoc and @mryburns; Dr. Nadira Hamid is the Global Co Principal Investigator for the study. MHIF is one of up to 70 global sites across the US and Europe, and the only one in MN.

Proud to enroll the first patient in the TRIVITA US IDE pivotal study for a new transcatheter tricuspid valve replacement system, advancing new treatment options for patients living debilitating symptoms of a leaky tricuspid heart valve: mplsheart.org/news/first-pat…

The Minneapolis Heart Institute Foundation, in collaboration with @AllinaHealth Minneapolis Heart Institute, is honored to be the first activated site to enroll a patient in the SMARTFLOW™ clinical study. Read the press release: mplsheart.org/news/celebrati…

We're live today | Emerging TTVR Platforms and the Future of Tricuspid Valve Replacement Join Dr @HamidNadira and explore how experienced operators are evaluating Intrepid, VDyne, Topaz, LuX and Laplace in everyday clinical practice. Last chance to register | 12:00 CDT | 13:00 EDT | 18:00 BST | Live Q&A | Secure your spot here 🔗radc.life/n6LROzPA Prof @drnvanmieghem Dr Firas Zahr Dr @SusheelKodaliMD @npfam1 (Dr Neil Fam) Prof @modine_thomas Dr @kashishgoelmd #TTVR #StructuralHeart #TricuspidValve #CardiologyEducation #HeartTeam

In three days, the next edition of Nail it with Nadira brings together some of the leading minds in structural heart intervention to discuss the next wave of TTVR innovation. Five platforms. One Heart Team. Real-world insight into the future of tricuspid valve replacement. 23 July | 12:00 CDT | 13:00 EDT | 18:00 BST | Live Q&A 👉 Register here radc.life/riHBXt1Z Dr @HamidNadira Prof @drnvanmieghem Dr Firas Zahr Dr @SusheelKodaliMD @npfam1 (Dr Neil Fam) Prof @modine_thomas Dr @kashishgoelmd #TTVR #StructuralHeart #TricuspidValve #CardiologyEducation #HeartTeam

As transcatheter tricuspid valve replacement technologies continue to evolve, a key question remains: Which platform is best suited for which patient? Join Dr @HamidNadira and an internationally recognised faculty for the next edition of Nail it with Nadira as they explore how emerging transcatheter tricuspid valve replacement technologies are best being used in clinical practice. 23 July | 12:00 CDT | 13:00 EDT | 18:00 BST | Live Q&A 👉 Register here radc.life/pRI2kx77 Prof @drnvanmieghem Dr Firas Zahr Dr @SusheelKodaliMD @npfam1 (Dr Neil Fam) Prof @modine_thomas Dr @kashishgoelmd #TTVR #StructuralHeart #TricuspidValve #CardiologyEducation #HeartTeam

What differentiates Intrepid, VDyne, Topaz, LuX and Laplace? Join Dr @HamidNadira and an internationally recognised faculty for the next edition of Nail it with Nadira as they explore how emerging transcatheter tricuspid valve replacement technologies are being used in clinical practice. 23 July | 12:00 CDT | 13:00 EDT | 18:00 BST | Live Q&A 👉 Register here radc.life/nKsgC475 Prof @drnvanmieghem Dr Firas Zahr Dr @SusheelKodaliMD @npfam1 (Dr Neil Fam) Prof @modine_thomas Dr @kashishgoelmd #TTVR #StructuralHeart #TricuspidValve #CardiologyEducation #HeartTeam

A huge thank you to Dr. @HamidNadira for stopping by the Rampart booth at #ASE2026! The conversations around head-of-the-table protection have been incredible. Interventional Echo deserves solutions built specifically for the way imagers work. The scatter radiation exposure in that position is real and significant, and it deserves protection at a level that lets you truly #ShedTheLead. We’re excited for what’s ahead with Vanguard. #ASE2026 #InterventionalEcho #RadiationProtection #Vanguard #Rampart #ShedTheLead #TotalBodyTotalTeamProtection #LeadFreeERPD #ERPD

🤖 The future is now. AI-assisted imaging and precision planning are redefining structural heart interventions with smarter workflows and enhanced guidance. Excellent presentation by @HamidNadira ! #ASE2026 #EchoFirst #iecho @ASE360

Last but never least at #ASE2026: “Tricuspid Valve Imaging for Transcatheter Therapies: The Essentials” (Joint with EACVI) 🫀 Expert speakers integrating anatomy, severity, mechanism, leaflet number/morphology, annular geometry, and RV function for imaging‑driven decision making.

ICE is becoming a key and integral part of procedures. However there's still much to learn! #cardioed #cardiotwitter

This week, a team of researchers quietly published in @JACCJournals one of the most profound studies of valvular heart disease in recent memory. The PREVUE-VALVE study used a decentralized, in-home echocardiography model to estimate the prevalence of valvular heart disease among U.S. adults aged 65–85. Importantly, this was not a clinic-based echo cohort; participants were recruited nationally and underwent comprehensive transthoracic echo in their homes, with studies interpreted by a core lab. That intentional design choice is critical: PREVUE-VALVE is a true prevalence study, accurately representing the true burden of valve disease in the U.S. population. The findings are striking: 8.2% of older Americans have moderate or greater valvular heart disease, and 18.4% have “clinically significant” disease when mild-to-moderate regurgitation is included. TR was the most common lesion, followed by AS, MR, AR, and MS. The burden rises sharply with age, reaching nearly 15% among adults aged 80–85. Extrapolated nationally, this means approximately 4.7 million Americans aged 65–85 currently have moderate or greater VHD, projected to increase to 6.5 million by 2060. Using the broader clinically significant definition, the number is already over 10 million and projected to approach 15 million. For structural heart programs, health systems, and policymakers, the message is clear: the valve disease burden is large, growing, and will require thoughtful planning around screening, access, and treatment capacity. Congratulations to @djc795, Michael 'Mickey' Brener MD MS, and all co-authors for a stunning glimpse into the present and future of valve disease! jacc.org/doi/epdf/10.1016/j.…

This analysis presented as SIMULTANEOUS PUBLICATION #EuroPCR from the CLEAR-IE registry evaluated percutaneous mechanical aspiration in patients with left-sided infective endocarditis. In a high-risk cohort, PMA was associated with high procedural success and a favourable rate of procedural complications despite the complexity of disease presentation. Read full paper 🔗eurointervention.pcronline.c… #Endocarditis #StructuralHeart #InterventionalCardio @NahyrLugo @benhibbertMDPhD @PedroMDMSc @SripalBangalore @MohammedQintar @SEH_MD @psorajja @HamidNadira @sahilparikhmd @aelsab

🚨Going live today! Nail it with Nadira: Electrosurgery in SESAME Septal Myotomy features Drs: @HamidNadira, @CathElectroSurg, @OKhaliqueMD, @ignamatsant and @FPaganiMD. This expert faculty will be discussing SESAME technique, imaging and procedural best practices in LVOT obstruction. Secure your spot 👉 radc.life/l29cp0SN #CardioX #Cardiology #StructuralHeart #Electrosurgery #SESAME #LVOTObstruction #StructuralHeartDisease #Haemodynamics

Excited to present, on behalf of all the investigators, the one-year outcomes from the AltaValve Early Feasibility Study. #SCAI2026 @bapat_savrtavr @HamidNadira @MHIValveDoc @JoaoLCavalcante @MHIF_Heart

🚨3 days to go | Nail it with @HamidNadira: Electrosurgery in SESAME Septal Myotomy 🗓️29 April | 08:00 EDT | 07:00 CDT | 14:00 CEST | Register here 👉 radc.life/EDgAB7Gi Join us for a deep dive into SESAME, imaging and transcatheter electrosurgery for LVOT obstruction. #CardioX #SESAME #SeptalMyotomy #StructuralHeart #Electrosurgery #LVOTO #InterventionalCardiology #Cardiology #Imaging

Electrosurgery meets structural heart innovation. 🔥 Join the next interactive 'Nail it with Nadira' webinar with Dr @HamidNadira and expert faculty to learn about SESAME septal myotomy and practical electrosurgery techniques for #LVOT obstruction. 📅 Wednesday 29 April 2026 ⏰08:00 EST | 06:00 CST | 14:00 CEST Sign up here and refer a colleague 👉 radc.life/1RyXwkZ7 @CathElectroSurg @OKhaliqueMD @ignamatsant @FPaganiMD #Cardiology #CardioX #TranscatheterAcademy #Electrosurgery #SESAME #CathLab #StructuralHeart

#NYValves2026 Looking forward to an exciting meeting!!! Can’t wait!